Novo Nordisk lifts curbs on Wegovy prescriptions in the U.S., says CEO
Novo Nordisk is lifting curbs on prescriptions of its weight-loss drug Wegovy in the United States and is increasing supply in that market, its CEO said on Wednesday.
Related Articles
Farmers protest in Hexham against “attack on rural economy”
The government says the current system is “unaffordable” but farmers say they face huge tax bills.
Teva Pharmaceutical third-quarter profit, revenue top estimates
Teva Pharmaceutical Industries reported a larger than expected rise in third-quarter profit, boosted by strong sales of copycat medicines and its branded drugs to treat…
How will Trump’s election change the FDA? History yields some clues
What will a second Donald Trump presidency mean for the regulation of medicines in the U.S.? History isn’t likely to repeat itself, but it will…
Cornwall research hub created by Univeristy of Exeter
Researchers will explore a range of topics including heatstroke and the likelihood of new pandemics.
Cornwall research hub created by Univeristy of Exeter
Researchers will explore a range of topics including heatstroke and the likelihood of new pandemics.
I’m Not Impressed With AI on Phones Yet. What It Will Take to Change My Mind
Commentary: The first wave of modern AI features feels more gimmicky than groundbreaking.
Stem cells can tailor their role in gene therapy based on the underlying disease, study suggests
RCCS San Raffaele Scientific Institute in Milan researchers have discovered that hematopoietic stem cells (HSCs) adapt their lineage commitment during gene therapy based on the…
Endocrine health in survivors of adult-onset cancer
Long-term survivors of cancer (ie, the patient who is considered cured or for whom the disease is under long-term control and unlikely to recur) are…
Donald Trump returns to the presidency with big ambitions to shake up health care
Trump promised to shake up public health institutions, reshape federal health programs, and slash high costs.
An oral non-covalent non-peptidic inhibitor of SARS-CoV-2 Mpro ameliorates viral replication and pathogenesis in vivo
Zhou et al. describe NZ-804, a non-peptidic inhibitor of the SARS-CoV-2 Mpro. It shows potent antiviral activity with low-nanomolar IC50 and EC50 in human lung cells…
